Citation Impact
2 from Science/Nature 81 standout
Citing Papers
Acute lymphoblastic leukaemia
2024 Standout
Understanding and targeting resistance mechanisms in cancer
2023 Standout
Works of Karen Small being referenced
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
2015
Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias
2010
Author Peers
| Author | PRM | Oncology | Genetics | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Karen Small | 392 | 511 | 170 | 268 | 23 | 769 | |
| James B. Orner | 60 | 254 | 5 | 32 | 12 | 497 | |
| Samantha Yang | 9 | 1 | 9 | 9 | 467 | ||
| Linmeng Wang | 6 | 18 | 483 | ||||
| Xiaojun Cai | 11 | 14 | 3 | 217 | 10 | 878 | |
| Yanlei Su | 2 | 5 | 1 | 48 | 12 | 359 |
All Works
Loading papers...